Audit of HbA1c Analysis and Reporting in the Presence of Variant Haemoglobins in Scotland 2020



J Johnstone on behalf of the ACB Scotland Audit Group

This questionnaire has been distributed to all laboratories across Scotland to assess variation in analysing and reporting HbA1c results in the presence of Haemoglobin variants between laboratories. HbA1c reporting was standardized in 2009, however, variant haemoglobins among the patient population present some difficulties. Different analytical systems are uniquely affected by some but not other variants, some of which may be quite prevalent in the local population. Identifying variants to clinicians in a comprehensible way and reporting – or not reporting – HbA1c results as appropriate is challenging and may benefit from a common approach.

Laboratory Name:						
Location:						
Health Board:						
Response only for this loca	nse only for this location $\ \square$ Response on behalf of all hospitals in Trust $\ \square$					
Details of individual respo	nding:					
Name:	Position:					
Contact details:						
	performed in your location then please forward to the in details above and complete question 1 before retucot					
<u> </u>	in your laboratory or do you refer this to another in-house in which department is this performed					
Referred to different Lal	ooratory					
Please indicate which la	boratory					
At this laboratory						
If at this lahoratory nlea	se indicate denartment:					

Method 1 Manufacturer Analyser				
_	•	•	•	
ernate method avai	lable?	Yes 🗆	No 🗆	
If yes please give do	etails:			
Method 2 Manufacturer Analyser				
Used only for variant	•			
Does your lab admi	inister noir	nt of care H	hA1c analy	sis – i e take resnonsihilit
Does your lab admit for analyser, reage	_		•	Please indicate if analyser operated by lab
-	nts, trainin	g etc. If yes	please give	e details: Please indicate if
	Manufacturer Analyser Do you have a seco at point-of-care, for ernate method availatives please give de Method 2 Manufacturer Analyser Used only as POCT a Used only for varian Used for both	Manufacturer Analyser Do you have a secondary meth at point-of-care, for dealing we ernate method available? If yes please give details: Method 2 Manufacturer Analyser Used only as POCT analyser Used only for variant analysis	Manufacturer Analyser Do you have a secondary method (Methorat point-of-care, for dealing with variants ernate method available? Yes If yes please give details: Method 2 Manufacturer Analyser Used only as POCT analyser Used only for variant analysis Used for both	Manufacturer Analyser Do you have a secondary method (Method 2) and if at point-of-care, for dealing with variants or other (ernate method available? Yes No If yes please give details: Method 2 Manufacturer Analyser Used only as POCT analyser Used only for variant analysis Used for both

Dealing with haemoglobinopathies.

0.	apply.	naemogiob	ins detected i	n your labor	atory	i ick a	n mat	
	Does method iden	tify variants	s?					
	Method 1 Yes	No		Method 2	Yes		No	
	If "yes" how are t	hese indica	ited?	Method 1		Meth	od 2	
	Analyser alerts Scrutiny of chrom	atograms						
	Grade of staff chec	cking chrom	atograms: _					
	Known patients "f	Analy LIMS	yser software S r (please speci	□ □ □				
	Does method iden Method 1 Yes	tify variant	type?	Method 2 Yes □		No 🗆		
7.	Does your labora that apply)?		a record of pr		ntified v			all
	Paper record Electronic reco Flags within in		□ □ oftware □					
8.	If HbA1c is unrepalternative (tick			you perfori	n or rec	comm	end an	
	HbA1c analysis au Sample sent to and Alternative analys Fructosamine sug Fructosamine add No alternative offe Other (please spec	other labora sis suggested gested led if serum ered or reco	tory for HbA1 l but not sent/ sample availab	c analysis by uperformed au	ınaffect	ed met	chod	

Please indicate alternate te immunoassay etc.	Please indicate alternate testing used/recommended e.g., HbA1c immunoassay etc.				
9. Is further investigation of n laboratory?	Is further investigation of new haemoglobinopathies recommended by your laboratory?				
. .	tomatically in own hospital/trust r genetic testing at referral laboratory o if desired.				
10.How are variant haemoglob apply)?	oins communicated to clinicians (tick	all that			
n the results field of your LIMS					
n laboratory comments					
By letter, e-mail or phone					
Other (please specify)					

11. How are results reported in the following scenarios?

11 a) NEWLY DETECTED VARIANTS

Variant			
	HbA1c reported Yes/no	Variant type reported (if known) Yes/no	If a comment is appended to the report, please include it below
High HbF: Below manufacturer cut-off			
Above manufacturer cut-off			
Non-interfering variant			
Interfering variant with reportable HbA1c			
Interfering variant with unreportable HbA1c			

11 b) PREVIOUSLY IDENTIFIED VARIANTS

Variant			
	HbA1c reported Yes/no	Variant type reported (if known) Yes/no	If a comment is appended to the report, please include it below
High HbF: Below manufacturer cut-off		·	
Above manufacturer cut-off			
Non-interfering variant			
Interfering variant with reportable HbA1c			
Interfering variant with unreportable HbA1c			